A Role for Transcription Factor STAT3 Signaling in Oncogene Smoothened-driven Carcinogenesis*1

Dongsheng Gu1, Qipeng Fan1, Xiaoli Zhang, and Jingwu Xie2

From the Wells Center for Pediatric Research, Departments of Pediatrics, Biochemistry/Molecular Biology and Pharmacology/Toxicology, The Simon Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana 46074

Background: Activated Hh signaling drives skin cancer development.

Results: Activated Hh signaling in mice increases IL-11, IL-11Ra, and STAT3 phosphorylation. STAT3 or IL-11Ra knockout reduces SmoM2-mediated carcinogenesis. The Smo agonist alone induces STAT3 phosphorylation in an IL11Ra-dependent manner.

Conclusion: The IL-11Ra/STAT3 signaling axis is required for Hh-mediated carcinogenesis.

Significance: This is the first report to link STAT3 signaling to Hh-mediated carcinogenesis.

Activation of the Hedgehog (Hh) pathway is known to drive development of basal cell carcinoma and medulloblastomas and to associate with many other types of cancer, but the exact molecular mechanisms underlying the carcinogenesis process remain elusive. We discovered that skin tumors derived from epidermal expression of oncogenic Smo, SmoM2, have elevated levels of IL-11, IL-11Ra, and STAT3 phosphorylation at Tyr705. The relevance of our data to human conditions was reflected by the fact that all human basal cell carcinomas examined have detectable STAT3 phosphorylation, mostly in keratinocytes. The functional relevance of STAT3 in Smo-mediated carcinogenesis was revealed by epidermal specific knockout of STAT3. We showed that removal of STAT3 from mouse epidermis dramatically reduced SmoM2-mediated cell proliferation, leading to a significant decrease in epidermal thickness and tumor development. We also observed a significant reduction of epidermal stem/progenitor cell population and cyclin D1 expression in mice with epidermis-specific knockout of STAT3. Our evidence indicates that STAT3 signaling activation may be mediated by the IL-11/IL-11Ra signaling axis. We showed that tumor development was reduced after induced expression of SmoM2 in IL-11Ra null mice. Similarly, neutralizing antibodies for IL-11 reduced the tumor size. In two Hh-responsive cell lines, ES14 and C3H10T1/2, we found that addition of Smo agonist purmorphamine is sufficient to induce STAT3 phosphorylation at Tyr705, but this effect was abolished after IL-11Ra down-regulation by shRNAs. Taken together, our results support an important role of the IL-11Ra/STAT3 signaling axis for Hh signaling-mediated signaling and carcinogenesis.

The Hh pathway plays an important role in cell differentiation, tissue polarity, cell proliferation, and carcinogenesis (1–5). The seven transmembrane domain-containing protein smoothened (SMO)3 serves as the key player for signal transduction of this pathway, whose function is inhibited by another transmembrane protein, Patched (PTC), in the absence of Hh ligands. Binding of Hh to its receptor PTC releases this inhibition, allowing SMO to signal downstream, leading to formation of active forms of Gli transcription factors. Gli molecules can regulate target gene expression by direct association with a specific sequence located at the promoter region of the target genes (6).

Most BCCs and a subset of medulloblastomas have constitutive activation of Hh signaling because of genetic mutations of PTCH1, SMO, or Su(Fu) (7–16). Mice with tissue-specific expression of oncogenic SMO (6) or Ptch1+/− (17) develop spontaneous BCC-like tumors (11) and medulloblastomas. Thus, activation of Hh signaling can drive the development of these tumors. Furthermore, Hh signaling activation has been reported in a variety of human cancers, including gastrointestinal, lung, prostate, and breast cancers (reviewed in Refs. 1, 5, 18, 19).

Although the biological relevance of Hh signaling to human cancer is very clear, the molecular basis by which Hh signaling induces cell proliferation and carcinogenesis remains largely elusive. Although several downstream mediators for BCC development have been described, including BCL2 (20, 21), PDGFRα (22), CD95 (12, 23), and BMI1 (24), we do not know the actual contribution of these mediators to Hh-induced BCC carcinogenesis. Increasing evidence indicate the importance of signaling cross-talks between Hh signaling and other pathways during carcinogenesis, such as PI3K-AKT, p53, wnt, and epidermal growth factor receptor signaling (reviewed in Refs. 1, 5).

It is not clear how these cross-talks contribute to tumor initiation or tumor progression.

To study the molecular mechanisms underlying BCC development, we compared gene expression between SmoM2-mediated tumors and normal skin keratinocytes and discovered a significant increase in expression of IL-11 and IL-11Ra, 2

1 Both authors contributed equally to this work.
2 To whom correspondence should be addressed: The Well Center for Pediatric Research, 1044 W. Walnut St., Indianapolis, IN 46202. Tel.: 317-278-3999; Fax: 317-274-8046; E-mail: jinxie@iupui.edu.
3 The abbreviations used are: SMO, smoothened; PTC, Patched; Hh, Hedgehog; BCC, basal cell carcinoma; SCC, squamous cell carcinoma.
upstream stimulators of STAT3 signaling. As an important proto-oncogene, STAT3 is known to regulate hair follicle stem cell population and skin wound healing and is critical for skin carcinogenesis of SCCs. To understand the significance of STAT3 signaling for BCCs, we used tissue-specific gene knock-out of STAT3 or down-regulation of its upstream activator IL-11Rα in the mouse model of BCCs. By examining the effects of these genetic deficiencies on tumor development, we revealed a critical role of the IL-11Rα/STAT3 signaling axis for Hh-mediated carcinogenesis.

EXPERIMENTAL PROCEDURES

Mice—K14-cre mice (25) were obtained from the Emice program. K14creER (26), IL11Ra knockout (27), and R26-SmoM2YFP mice (28) were purchased from The Jackson Laboratories (Bar Harbor, Maine). Mice were maintained and mated under pathogen-free husbandry conditions. Mice with conditional knockout of STAT3, generated as described previously, were generously provided by Dr. Xin-Yuan Fu (29). Gli1 null mice were provided by Alex Joyner (30). To obtain a Gli1 null background in K14cre+/SmoM2+ mice, Gli1 null mice were mated with K14cre and R26-SmoM2YFP mice separately. The resulting Gli1+/− mice with K14cre+ or SmoM2+ were mated to obtain K14cre−SmoM2−Gli1−− mice. To obtain IL-11Ra null mice with K14creER+ and SmoM2YFP+, we first generated IL11Ra+/−/K14creER+/SmoM2YFP+ mice, and these mice were then mated to each other to obtain the right genotypes (IL11Ra+/−/K14creER+/SmoM2YFP+, IL11Ra+/−/K14creER+/SmoM2YFP+, and IL11Ra−−/K14creER+/SmoM2YFP+). The off-spring from the mating was screened using PCR to determine their transgenic status according to the instruction reported previously. SmoM2 expression in these mice was induced by oral administration of tamoxifen according to a protocol published previously (26). Neutralizing anti-
Expression of Hh target genes was examined by PCR, as digestion of epidermis with collagenase IV for 2 h at 37 °C. Epidermal single cells were obtained by extraction with the Ambion RNA extract kit and the rest for forceps. One part of the epidermis was used for total RNA extraction with the Ambion RNA extract kit and the rest for single cell isolation. Epidermal single cells were obtained by digestion of epidermis with collagenase IV for 2 h at 37 °C. Expression of Hh target genes was examined by PCR, as reported previously (31).

Immunofluorescent and Immunohistochemistry Staining—Mouse skin tissues were embedded in paraffin (for paraffin section) or optimal cutting temperature. Tissue sections of 5-μm thickness were prepared for immunohistochemistry using a biotin-based staining kit from DAKO, as described previously (12). Specific antibodies to pSTAT3-Y705 and Cyclin D1 were purchased from Cell Signaling Technology, Ki67 from ABCam, and Keratin 14 from Covance. For immunofluorescent staining, slides were first fixed in 4% paraformaldehyde at room temperature for 30 min. After blocking with horse serum, tissue sections were incubated with specific antibodies for 3 h, followed by fluorescence-labeling secondary antibodies for 1 h at room temperature. Thorough washing was performed between antibody incubations to reduce nonspecific staining. DAPI staining was used to stain nucleus.

RT-PCR and Real-time PCR—Total RNA was isolated from the tissues using Trizol reagent (Sigma) according to the instructions of the manufacturer. 1 μg of total RNA was reverse-transcribed into cDNAs using the first-strand synthesis kit (Roche). We performed real-time RT-PCR with a procedure reported previously (3).

EdU Labeling and Flow Cytometry—5-ethyl-2'-deoxyuridine (EdU) labeling was carried out 14 h before animal sacrifice by intraperitoneal injection of EdU solution according to the instructions of the manufacturer (32). Single cells from epidermis were subjected to antibody staining to recognize CD11b, Gr1, CD34, and CD49F. Antibodies with fluorescent labeling were purchased from eBioscience and were incubated with cells for 30 min on ice (with 1:200 dilutions). Cells were further incubated with DAPI just before flow cytometry analysis. DAPI-negative cells (live cells) were gated for expression analysis of specific cell surface markers.

Cell Culture and ShRNA Expression—C3H10T1/2 and ES14 cells were cultured as described previously (33). ShRNAs to IL-11Rα were purchased from Sigma and were introduced into cells via lentivirus-mediated gene expression. Of the five ShRNAs tested, two independent ShRNAs were shown to reduce expression of IL-11Rα and were used in this study. To stimulate Hh signaling activation, the Smo agonist purmorphamine (at 5 μM) was added to the culture medium. Protocols for motor neuron differentiation and induction of alkaline phosphatase have been described previously (33).

Western Blot Analysis—Epidermis was first lysed with a protein loading buffer in ultrasound bath for 5 min. Specific antibodies to STAT3, pSTAT3-Y705, and cyclin D1 were purchased from Cell Signaling Technology, Inc. Proteins were detected according to a procedure reported previously (34).

Statistical Analyses—were performed using Student’s t test (two-tailed) to compare the results, with p values of < 0.05 indicating a statistically significant difference.

RESULTS

Activation of STAT3 Signaling in SmoM2-mediated Skin Tumors—Almost all basal cell carcinomas contain activated Hh signaling, resulting frequently from inactivated mutation of tumor suppressor gene PTCH1 or gain-of-function mutation of proto-oncogene Smo. Skin-specific expression of mutant Smo, SmoM2, via mating of R26-SmoM2YFP mice (28) with K14-cre mice (25) exhibits phenotypes of BCCs (33) and is regarded as an important model for studying Hh-mediated carcinogenesis. To further understand molecular bases of Hh-mediated carcinogenesis, we performed gene expression profiling of SmoM2YFP-expressing keratinocytes using Affymetrix arrays and revealed changes in several cytokine molecules that are known to associate with STAT3 signaling (33). To confirm the
data from the gene expression arrays, we first used real-time PCR to detect expression of STAT3 signaling activators in epidermis with or without SmoM2 expression. As expected, we detected activation of the Hh pathway, as indicated by elevated expression of the Hh target gene Gli1 in mice with SmoM2 expression (33) (supplemental Fig. 1). In addition, expression of several STAT3 signaling activators, TGFα, IL-11Rα, and IL-11, was elevated in epidermis with SmoM2 expression (Fig. 1, A–C). EGF, KGF, and IL-6, other putative STAT3 activators, were not significantly changed by SmoM2 expression (Fig. 1, D–F). The level of IL-11Rα expression, not IL-11 and TGFrα, was dramatically reduced in keratinocytes after knockout of the downstream transcription factor Gli1 (Fig. 1G), suggesting that IL-11Rα may be regulated by Hh signaling. These results indicate that activation of Hh signaling in mouse epidermis mediates activation of STAT3 signaling.

Phosphorylation at a critical tyrosine residue, Tyr705, induces STAT3 dimerization through phosphotyrosine-SH2 domain interaction, resulting in its nuclear localization and target gene expression (35). We examined whether the level of STAT3 phosphorylation is induced in epidermis by SmoM2 expression. Western blot analysis revealed a higher level of STAT3 phosphorylation in epidermis of K14cre/R26-SmoM2 mice (Fig. 1, A–C). EGF, KGF, and IL-6, other putative STAT3 activators, were not significantly changed by SmoM2 expression (Fig. 1, D–F). The level of IL-11Rα expression, not IL-11 and TGFrα, was dramatically reduced in keratinocytes after knockout of the downstream transcription factor Gli1 (Fig. 1G), suggesting that IL-11Rα may be regulated by Hh signaling. These results indicate that activation of Hh signaling in mouse epidermis mediates activation of STAT3 signaling.

To demonstrate the significance of STAT3 signaling in Hh signaling-mediated tumors, we generated mice with keratin 14 promoter-driven STAT3 knockout in our mouse model of BCCs. We predict that if STAT3 signaling is important for SmoM2-mediated tumor development, deletion of STAT3 in the epidermis should reduce tumor formation in K14cre/R26-SmoM2 mice. Deletion of STAT3 was confirmed in the skin epidermis by Western blotting (Fig. 3A) and immunohistochemistry (supplemental Fig. 2). In the absence of SmoM2 expression, K14Cre-mediated STAT3 knockout had no visible phenotypes, suggesting STAT3 knockout does not affect the viability of mice, which was consistent with a previous study (36). Skin histology of mice with or without STAT3 in K14cre/SmoM2 mice was further examined. We found that SmoM2-expressing mice without STAT3 had a 70% reduction in skin thickness (Fig. 3, B and C). The percentage of tumor area in the epidermis was also reduced from 50% to 30% (Fig. 3, D). To examine the cellular effects of STAT3 in mouse skin, we first examined cell proliferation following EDU labeling (32). EDU labeling was increased in K14cre+SmoM2 mice but was reduced to the basal level after STAT3 knockout (Fig. 4, A and B). Expression of Ki-67, another marker for cell proliferation, was also reduced in STAT3 knockout tumor specimens (Fig. 4, C and D). However, there were no significant changes in the level of active caspase 3, a marker for cell apoptosis in skin tissues without STAT3 (data not shown).
not shown). These results indicate that STAT3 ablation in epidermis significantly reduces SmoM2-mediated cell proliferation and tumor development.

**FIGURE 4. The effect of STAT3 knockout on cell proliferation in SmoM2-expressing epidermis.** We compared K14cre\(^{-}\)/SmoM2\(^{YFP}\)/STAT3\(^{wt}\) mice with K14cre\(^{-}\)/SmoM2\(^{YFP}\)/STAT3\(^{f/f}\) mice for cell proliferation in epidermis by EdU labeling and Ki-67 staining. EdU labeling was performed 14 h before animal sacrifice, and positive cells were analyzed by flow cytometry (A). B, data summary from all mice from each group. The percentage of EdU-positive cells in tumor-bearing K14cre\(^{-}\)/SmoM2\(^{YFP}\)/STAT3\(^{wt}\) mice (K14cre\(^{-}\)/SmoM2\(^{YFP}\)/STAT3\(^{f/f}\)) compared with that from K14cre\(^{-}\)/SmoM2\(^{YFP}\)/STAT3\(^{f/f}\) mice (K14cre\(^{-}\)/SmoM2\(^{YFP}\)/STAT3\(^{f/f}\)) (\(p < 0.0001\)). Immunohistochemistry was performed with specific antibodies to Ki-67 (C), and the number of Ki-67 positive cells/field (\(\times 200\), one field = 0.9 mm\(^2\)) was counted under the microscope. The number of positive cells shown in D was an average from five mice (eight fields per mouse). *, \(p < 0.05\).

**Alteration of Epidermal Stem/Progenitor Cell Population following STAT3 Knockout**—Like many types of cancer, skin cancer BCC is composed of many cell types: epidermal keratino-
STAT3 Signaling in Oncogene Smoothened-driven Carcinogenesis

...cytes, stem/progenitor cells, fibroblasts, a variety of T cells, and myeloid-derived cells. Using flow cytometry, we detected a significant increase in the epidermal stem/progenitor cell population (indicated by expression of CD34 and CD49F) in K14cre+ SmoM2YFP+ mice (39) (Fig. 5, A and B, and supplemental Fig. 3). We did not observe significant changes in other cell populations. As indicated in Fig. 5, A and B, the population of CD34/CD49F-positive cells, the putative epidermal stem/progenitor cells, was increased significantly in SmoM2-expressing epidermis but was decreased in mice without epidermal STAT3. This effect appears to be STAT3-specific because we did not observe alteration of the Hh target gene Gli1 after STAT3 knockout (supplemental Fig. 1). Furthermore, expression of the Lgr6 transcript, another marker for BCC stem/progenitor cells, was increased in epidermis of Cre+ SmoM2YFP+ mice (39) (Fig. 5, A and B, and supplemental Fig. 3). We did not observe significant changes in other cell populations. As indicated in Fig. 5, A and B, and...
tion in SmoM2-mediated carcinogenesis is regulated largely by STAT3 signaling.

Effects of IL-11R/H9251 and IL-11 Down-regulation on SmoM2-mediated Tumor Formation—If the IL-11/IL-11R/H9251 signaling axis is responsible for STAT3 activation during BCC development, down-regulation of IL-11R/H9251 or IL-11 should reduce SmoM2-mediated tumor formation. We generated mice with epidermis-specific SmoM2 expression in IL-11R/H9251/H11001/H11002 or H11002/H11002 background. As shown in Fig. 7, A and B, skin thickness was reduced over 50% in IL-11R/H9251/H11002 and over 70% in IL-11R/H9251/H11002/H11002 mice. The level of STAT3 phosphorylation was barely detectable in IL-11/H11002/H11002 mice (Fig. 7 C). Even in IL-11/H11001/H11002 mice, the level of STAT3 phosphorylation was reduced significantly. Consistent with the data from epidermis-specific knockout of STAT3, cell proliferation, as indicated by Ki-67 staining, was reduced significantly in IL-11R/H9251/H11002 mice (supplemental Fig. 5, A and B). We also noticed a significant reduction of Lgr6 expression, a marker for epidermal stem cell marker, in IL-11Rα−/−/SmoM2+/+K14creER mice (supplemental Fig. 5C). Cyclin D1 in tumors of IL-11Rα+/+ or IL-11Rα−/− mice was also markedly reduced (Fig. 7C). These results indicate that IL-11Rα is a critical factor in mediating STAT3 activation and tumor development in this BCC model.

IL-11Rα serves as the specific cytokine receptor for IL-11 by forming a hexamer complex with gp130 and IL-11 to activate the downstream effector STAT3 (45). If the IL-11/IL-11Rα signaling axis is the major contributor for STAT3 activation, we predicted that depleting IL-11 in the tumor microenvironment should reduce tumor size. To test this hypothesis, we treated skin lesions with neutralizing antibodies for IL-11 via subcutaneous injection (5 mg of PBS). Mouse IgG proteins were used as control. We found that although skin lesions with control IgG treatment had ~50% tumor/tissue area, treatment with IL-11 neutralizing antibodies reduced the tumor to ~35% (supplemental Fig. 6, A and B). Further analyses indicated that skin areas injected with IL-11 neutralizing antibodies had a reduced level of STAT3 phosphorylation (supplemental Fig. 6C). These results are consistent with our data from epidermis-specific

### FIGURE 6. Regulation of Cyclin D1 expression by STAT3 signaling in SmoM2-mediated carcinogenesis.  
Expression of several putative STAT3 target genes in tumor-bearing epidermis was assessed by real-time PCR. These genes include cyclin D1 (A), BCL-XL (B), HSP70 (C), and Survivin (D). Following STAT3 ablation in epidermis, SmoM2-induced expression of cyclin D1 was examined at the protein level, which was detected by Western blotting (E). Please note that STAT3 ablation in epidermis did not completely wipe out all cyclin D1 expression. To rule out the possibility that the effect of STAT3 knockout was due to nonspecific regulation of Hh signaling, we detected Hh target gene expression from skin tissues of K14cre-Rosa26-SmoM2/STAT3+/+ mice or K14cre-Rosa26-SmoM2/STAT3flp/flp mice, with the K14 transcript as the internal control (supplemental Fig. 1), and found that Gli1 expression was not significantly altered by STAT3 depletion. *p < 0.05.
knockout of STAT3 or IL-11R knockout. Thus, it appears that interruption of any part of the IL-11R/STAT3 signaling axis is sufficient to inhibit SmoM2-mediated carcinogenesis.

Reducing IL-11R Expression Prevents Smo-mediated STAT3 Phosphorylation—To demonstrate direct regulation of STAT3 activity by Hh signaling, we chose two Hh-responsive cell lines: mouse ES cell line ES14 and mesenchymal stem cell line C3H10T1/2. We showed previously that addition of Smo agonist purmorphamine in these two cell lines induces Hh target gene expression (33). As shown in Fig. 8A, we also observed elevated expression of IL-11Ra in response to purmorphamine treatment in both cell lines. Furthermore, we detected an increase in the level of STAT3 phosphorylation (Fig. 8, B and C, top left panels). To test whether IL-11Ra mediates Smo-induced STAT3 signaling activation, we used specific shRNAs to down-regulate IL-11Ra expression. After treatment of these cells with purmorphamine, we detected STAT3 phosphorylation. If IL-11Ra is the major factor for Hh-mediated STAT3 phosphorylation, down-regulation of IL-11Ra should be able to prevent purmorphamine-induced STAT3 phosphorylation. As shown in Fig. 8, B and C, top right panels, we found that STAT3 phosphorylation was not induced by purmorphamine in cells with down-regulation of IL-11Ra. The effect of purmorphamine was more dramatic in ES14 cells than C3H10T1/2 cells. In C3H10T1/2 cells the effect of purmorphamine was not as dramatic, but down-regulation of IL-11Ra significantly reduced the basal level of STAT3 phosphorylation. The high basal level of IL-11/IL-11Ra expression in C3H10T1/2 cells (data not shown) may be responsible for this effect. IL-11Ra down-regulation abolished Hh-mediated motor neuron differentiation and alkaline phosphatase expression (a marker for osteoblast differentiation (supplemental Fig. 7).

In summary, we found that Hh signaling activation induces STAT3 phosphorylation through regulation of IL-11Ra in mouse models of BCC and in two Hh-responsive cell lines. We demonstrated that disruption of the IL-11Ra/STAT3 signaling axis either by epidermis-specific knockout of STAT3, IL-11Ra knockout, or subcutaneous injection of IL-11 neutralizing antibodies significantly reduced cell proliferation, skin stem/progenitor cell population, and tumor development. Using Hh-responsive ES cells, we showed that down-regulation of IL-11Ra alone is sufficient to abolish Hh-mediated STAT3 activation and cell differentiation processes. These data indicate that the IL-11Ra/STAT3 signaling axis plays a critical role in Hh-mediated biological processes.

DISCUSSION

As a key player in Hh signaling, activated mutations of smoothened are known to cause development of cancer. Tissue-specific expression of Smo mutant SmoM2 in mice greatly contributes to our understanding of Hh-mediated carcinogenesis (28, 33, 46–51). Currently, it is not very clear which specific molecules mediate Hh-signaling in cancer development. In this study, we discovered an important role of the IL-11Ra/STAT3 signaling axis in Hh-mediated cell functions and carcinogenesis. STAT3 signaling is a known pathway critical for development of many cancer types, including skin cancer (52). Through epidermis-specific gene
knockout of STAT3, IL-11R/H9251 knockout, and subcutaneous injection of IL-11-neutralizing antibodies, we demonstrated a critical role of the IL-11R/H9251/STAT3 signaling axis for regulation of cell proliferation, epidermal stem/progenitor cell expansion, and tumor development. Because of the fact that isolated BCC cells lose Hh signaling once culture in dishes, we chose two Hh-responsive cell lines to demonstrate that addition of Smo agonist purmorphamine induces STAT3 phosphorylation directly, and down-regulation of IL-11R/H9251 abolishes this effect, supporting the critical role of IL-11R/H9251 for Hh-induced STAT3 signaling. In contrast, IL-11 expression was induced during BCC formation but was not affected by Gli1 knockout. On the basis of these results, we believe that unlike IL-11Rα, IL-11 is indirectly regulated by Hh signaling. The effects of IL-11/IL-11Rα are mediated by a multimeric complex comprising IL-11, the ligand binding IL-11Rα, and the ubiquitously expressed gp130R. As a result, STAT3 signaling is activated during SmoM2-mediated carcinogenesis (see supplemental Fig. 8 for the model).

Like IL-6, the cellular response of IL-11 is determined by the more restricted expression level of the specific α-receptor subunit IL-11Rα. There are two IL-11Rα isoforms, but only expression of IL-11Rα1 was altered in the BCC model (data not shown). As a member of IL-6 cytokine family, IL-11 can exert both immunomodulatory effects as well as epithelial effects (45). When STAT3 was knocked out in the epidermis, we did not observe any changes in myeloid-derived cell population (CD11b/Gr1 cells), indicating that the immunomodulatory effects of IL-11 do not play a dominant role in the BCC model. In contrast, we observed significant changes in expression of cyclin D1 (Fig. 6), cell proliferation (Fig. 4), and stem/progenitor cell population (Fig. 5). Thus, our data strongly support a non-immunomodulatory effect of the IL-11Rα/STAT3 signaling axis in the BCC model.

In the last few years, elevated expression of IL-11Rα and STAT3 signaling has been reported in a number of cancer types, including osteosarcomas, prostate cancer, and gastric carcinomas (53–56). In a mouse model of gastric cancer, it is demonstrated that IL-11Rα knockout prevents tumor formation (57). It is not clear what regulates the abnormally high expression of IL-11Rα, and it will be interesting to examine whether Hh signaling plays a role in these cancers.

**FIGURE 8. Requirement of IL-11Rα for Hh signaling-induced STAT3 phosphorylation.** A, expression of IL-11Rα in ES14 and C3H10T1/2 (10t) cells in presence of purmorphamine (AG). B, STAT3 phosphorylation in Hh-responsive mouse ES14 cells following treatment with Smo agonist AG. C, STAT3 phosphorylation in C3H10T1/2 cells in the presence or absence of AG. In B and C, the top panels show the Western blotting images, and the bottom panels show the analysis of the images (averaged from three independent experiments). *, p < 0.05. Note the low levels of STAT3 phosphorylation after IL-11Rα down-regulation (IL11Ra−/−).
Our studies are consistent with the data from two-stage skin carcinogenesis studies in which keratinocyte-specific knockout of STAT3 prevents the 12-methylbenz(α)anthracene/12-O-tetradecanoylphorbol-13-acetate-induced development of SCC (58). Previous studies indicate that STAT3 can be activated by the epidermal growth factor receptor (59). Although SCC can be induced by the 12-methylbenz(α)anthracene/12-O-tetradecanoylphorbol-13-acetate, BCCs only develop after activation of the Hh signaling pathway via loss of function of Ptch1 or activation of SmoM2. In our mouse model, we did observe significant changes in expression of epidermal growth factor receptor ligand TGFα but not EGF or KGF. In addition, we observed significant expression of IL-11 and IL-11Ra, suggesting that the triggers of STAT3 activation in our system may be different from that of the SCC model. Like other studies, our study only removed STAT3 signaling in the epidermis. Thus, the stromal effects of STAT3 cannot be concluded in our study. STAT3 signaling in tumor stroma is known to be responsible for regulation of myeloid-derived suppressor cells in a variety of cancers (39). Because of the lethality from STAT3 knockout, for regulation of myeloid-derived suppressor cells in a variety of cancers (39). Because of the lethality from STAT3 knockout, our studies are consistent with the data from two-stage skin carcinogenesis studies in which keratinocyte-specific knockout of STAT3 prevents the 12-methylbenz(α)anthracene/12-O-tetradecanoylphorbol-13-acetate-induced development of SCC (58).

In summary, our data provide evidence to support the following picture. SmoM2 induces expression of IL-11Ra in keratinocytes. Together with elevated expression of IL-11 in the tumor microenvironment, STAT3 signaling is activated. As a result of STAT3 activation, cyclin D1 expression is up-regulated, leading to increased cell proliferation, epidermal stem/progenitor cell accumulation, and development of BCCs (see details in supplemental Fig. 8 for our model).

Acknowledgments—We thank Drs. Xin-Yuan Fu and Weinian Shou for providing STAT3F/F mice and Dr. Alex Joyner for providing Gli1 null mice.

REFERENCES

1. Yang, L., Xie, G., Fan, Q., and Xie, J. (2010) Activation of the hedgehog signaling pathway in human cancer and the clinical implications. Oncogene 29, 469–481.
2. Parkin, C. A., and Ingham, P. W. (2008) The adventures of Sonic Hedgehog in development and repair. Am. J. Physiol. Gastrointest. Liver Physiol. 294, G363–367.
3. Jiang, J., and Hui, C. C. (2008) Hedgehog signaling in development and cancer. Dev. Cell 15, 801–812.
4. McMahon, A. P., Ingham, P. W., and Tabin, C. J. (2003) Developmental roles and clinical significance of hedgehog signaling. Curr. Top. Dev. Biol. 53, 1–114.
5. Epstein, E. H. (2008) Basal cell carcinomas. Attack of the hedgehog. Nat. Rev. Cancer 8, 743–754.
6. Kinzler, K. W., and Vogelstein, B. (1990) The GLI gene encodes a nuclear protein which binds specific sequences in the human genome. Mol. Cell. Biol. 10, 634–642.
7. Johnson, R. L., Rothman, A. L., Xie, J., Goodrich, L. V., Bare, J. W., Bonifas, J. M., Quinn, A. G., Myers, R. M., Cox, D. R., Epstein, E. H., Jr., and Scott, M. P. (2006) Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 272, 1668–1671.
8. Hahn, H., Christiansen, J., Wicking, C., Zaphiropoulos, P. G., Chidambaram, A., Gerrard, B., Vorechovsky, I., Bale, A. E., Toftgard, R., Dean, M., and Wainwright, B. (1996) A mammalian patched homolog is expressed in target tissues of sonic hedgehog and maps to a region associated with developmental abnormalities. J. Biol. Chem. 271, 12125–12128.
9. Hahn, H., Wicking, C., Zaphiropoulous, P. G., Gailani, M. R., Shanley, S., Chidambaram, A., Vorechovsky, I., Holmberg, E., Unden, A. B., Gillies, S., Negus, K., Smyth, I., Pressman, C., Leffell, D. J., Gerrard, B., Goldstein, A. M., Dean, M., Toftgard, R., Chenexiv-Trench, G., Wainwright, B., and Bale, A. E. (1996) Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 85, 841–851.
10. Hahn, H., Wojnowski, L., Zimmer, A. M., Hall, J., Miller, G., and Zimmer, A. (1998) Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. Nat Med 4, 619–625.
11. Aszterbaum, M., Epstein, J., Oro, A., Douglas, V., LeBoit, P. E., Scott, M. P., and Epstein, E. H. (1999) Ultraviolet and ionizing radiation enhance the growth of BCCs and trichoblastomas in patched heterozygous knockout mice. Nat. Med. 5, 1285–1291.
12. Athar, M., Li, C., Tang, X., Chi, S., Zhang, X., Kim, A. L., Tyring, S. K., Kopelovich, L., Hebert, J., Epstein, E. H., Jr., Bickers, D. R., and Xie, J. (2004) Inhibition of smoothened signaling prevents ultraviolet B-induced basal cell carcinomas through regulation of Fas expression and apoptosis. Cancer Res. 64, 7545–7552.
13. Xie, J., Murone, M., Luoh, S. M., Ryan, A., Gu, Q., Zhang, C., Bonifas, J. M., Lam, C. W., Hynes, M., Goddard, A., Rosenthal, A., Epstein, E. H., Jr., and de Sauvage, F. J. (1998) Activating Smoothened mutations in sporadic basal cell carcinoma. Nature 391, 90–92.
14. Reifenberger, J., Wolter, M., Knobbe, C. B., Köhler, B., Schönicke, A., Scharwächter, C., Kumar, K., Blaschke, B., Ruzicka, T., and Reifenberger, G. (2005) Somatic mutations in the PTCH, SMOH, SUFUH, and TP53 genes in sporadic basal cell carcinomas. Br. J. Dermatol. 152, 43–51.
15. Reifenberger, J., Wolter, M., Weber, R. G., Megahed, M., Ruzicka, T., Lichter, P., and Reifenberger, G. (1998) Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res. 58, 1798–1803.
16. Svärd, J., Heby-Henricson, K., Henricson, K. H., Persson-Lek, M., Rozell, B., Lauth, M., Bergström, A., Ericson, J., Toftgård, R., and Telegdon, S. (2006) Genetic elimination of Suppressor of fused reveals an essential repressor function in the mammalian Hedgehog signaling pathway. Dev. Cell 10, 187–197.
17. Goodrich, L. V., Milenković, L., Higgs, K. M., and Scott, M. P. (1997) Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 277, 1109–1113.
18. Metcalfe, C., and de Sauvage, F. J. (2011) Hedgehog fights back. Mechanisms of acquired resistance against Smoothened antagonists. Cancer Res. 71, 5057–5061.
19. Ng, J. M., and Curran, T. (2011) The Hedgehog’s tale. Developing strategies for targeting cancer. Nat. Rev. Cancer 11, 493–501.
20. Bigelow, R. L., Chari, N. S., Unden, A. B., Spurgers, K. B., Lee, S., Roop, D. R., Toftgard, R., and McDonnell, T. J. (2004) Transcriptional regulation of bcl-2 mediated by the sonic hedgehog signaling pathway through gli-1. J. Biol. Chem. 279, 1197–1205.
21. Regl, G., Kasper, M., Schindler, H., Eicher, T., Neill, G. W., Philpott, M. P., Esternbauer, H., Hauser-Kronberger, C., Frischau, M. A., and Abberger, F. (2004) Activation of the BCL2 promoter in response to Hedgehog/GLI signal transduction is predominantly mediated by GLI2. Mol. Cell. Biol. 24, 38365.
22. Hahn, H., Christiansen, J., Wicking, C., Zaphiropoulos, P. G., Gailani, M. R., Shanley, S., Chidambaram, A., Vorechovsky, I., Holmberg, E., Unden, A. B., Gillies, S., Negus, K., Smyth, I., Pressman, C., Leffell, D. J., Gerrard, B., Goldstein, A. M., Dean, M., Toftgard, R., Chenexiv-Trench, G., Wainwright, B., and Bale, A. E. (1996) Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 85, 841–851.
23. Xie, J., Murone, M., Luoh, S. M., Ryan, A., Gu, Q., Zhang, C., Bonifas, J. M., Lam, C. W., Hynes, M., Goddard, A., Rosenthal, A., Epstein, E. H., Jr., and de Sauvage, F. J. (1998) Activating Smoothened mutations in sporadic basal cell carcinoma. Nature 391, 90–92.
STAT3 Signaling in Oncogene Smoothened-driven Carcinogenesis

24. Leung, C., Lingbeek, M., Shakhova, O., Liu, J., Tanger, E., Sarembslani, P., Van Lohuizen, M., and Marino, S. (2004) Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature 428, 337–341

25. Jonkers, J., Meuwissen, R., van der Gulden, H., Peterse, H., van der Valk, M., Berens, and A. (2001) Synergistic tumor suppressor activity of BRC2a and p53 in a conditional mouse model for breast cancer. Nat. Genet. 29, 418–425

26. Vasioukhin, V., Degenstein, L., Wise, B., and Fuchs, E. (1999) The magical touch. Genome targeting in epidermal stem cells induced by tamoxifen application to mouse skin. Proc. Natl. Acad. Sci. U.S.A. 96, 8551–8556

27. Nandurkar, H. R., Robb, L., Tarlinton, D., Barnett, L., K"ontgen, F., and Begley, C. G. (1997) Adult mice with targeted mutation of the interleukin-11 receptor (IL11Ra) display normal hematopoiesis. Blood 90, 2148–2159

28. Mao, J., Ligon, K. L., Rahlin, E. Y., Thayer, S. P., Bronson, R. T., Rowitch, D., and McMahon, A. P. (2006) A novel somatic mouse model to survey tumorigenic potential applied to the Hedgehog pathway. Cancer Res. 66, 10171–10178

29. Kano, A., Wolfgang, M. J., Gao, Q., Jacoby, I., Chai, G. X., Hansen, W., Iwamoto, Y., Poher, J. S., Flavell, R. A., and Fu, X. Y. (2003) Endothelial cells require STAT3 for protection against endotoxin-induced inflammation. J. Exp. Med. 198, 1517–1525

30. Park, H. L., Bai, C., Platt, K. A., Beeghly, A., Hui, C. C., Nakashima, M., and Joyner, A. L. (2000) Mouse Gli1 mutants are viable but have defects in SHH signaling in combination with a Gli2 mutation. Development 127, 1593–1605

31. He, J., Sheng, T., Stelter, A. A., Li, C., Zhang, X., Sinha, M., Luxon, B. A., and Xie, J. (2006) Suppressing Wnt signaling by the hedgehog pathway through sFRP-1. J. Biol. Chem. 281, 35598–35602

32. Diermeier-Daucher, S., Clarke, S. T., Hill, D., Vollmann-Zwerenz, A., Bradford, J. A., and Brockhoff, G. (2009) Cell type specific applicability of the Src oncoprotein in mouse fibroblasts. Role of activated STAT3 signalling. Oncogene 28, 3271–3279

33. Sinibaldi, D., Wharton, W., Turkson, J., Bowman, T., Pledger, W. J., and Jove, R. (2000) Induction of p21WAF1/CIP1 and cyclin D1 expression by STAT3 activation in prostate carcinoma. Oncogene 19, 5419–5427

34. Snippert, H. J., Haegebarth, A., Kasper, M., Jaks, V., van Es, J. H., Barker, N., Nagai, H., Yasuda, Y., Sugano, K., and Mano, H. (2010) Identification of the transforming activity of Indian hedgehog by retroviral expression screening. Cancer Sci. 101, 60–64

35. Yu, H., Pardoll, D., and Jove, R. (2009) STATs in cancer inflammation and inhibition of GDC-0449 refractory smoothened mutants and downstream cytokine signaling in prostate cancer. Mol. Pharmacol. 75, 523–529

36. Hofmann, I., Stover, E. H., Cullen, D. E., Mao, J., Morgan, K. J., Lee, B. H., H., Yauch, R. L., and de Sauvage, F. J. (2011) Small molecule Hedgehog pathway inhibitors. Curr. Opin. Pharmacol. 11, 172–178

37. Youssef, K. K., Van Keymeulen, A., Lapouge, G., Beck, B.,Michaux, C., Achoury, Y., Sotiropoulou, P. A., and Blanpain, C. (2010) Identification of the cell lineage at the origin of basal cell carcinoma. Nat. Cell Biol. 12, 299–305

38. Grachtchouk, M., Pero, J., Yang, S. H., Ermilov, A. N., Michael, L. E., Wang, A., Wilbert, D., Patel, R. M., Ferris, J., Diener, J., Allen, M., Lim, S., Syu, J. I., Verhaegen, M., and Drugosz, A. A. (2011) Basal cell carcinomas in mice arise from hair follicle stem cells and multiple epithelial progenitor populations. J. Clin. Invest. 121, 1768–1781

39. Wang, G. Y., Wang, J., Mancianti, M. L., and Epstein, E. H., Jr. (2011) Basal cell carcinomas arise from hair follicle stem cells in Pcth1(+/−) mice. Cancer Cell 19, 114–124

40. Gao, J., Graves, S., Koch, U., Liu, S., Iankovic, V., Buonamici, S., El Andaloussi, A., Nimer, S. D., Kee, B. L., Taichman, R., Radtke, F., and Aifantis, I. (2009) Hedgehog signaling is dispensable for adult hematopoietic stem cell function. Cell Stem Cell 4, 548–558

41. Hofmann, I., Stover, E. H., Cullen, D. E., Mao, J., Morgan, K. J., Lee, B. H., Kharas, M. G., Miller, P. G., Cornejo, M. G., Okabe, R., Armstrong, S. A., Ghilardi, N., Gould, S., de Sauvage, F. J., McMahon, A. P., and Gilliland, D. G. (2009) Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis. Cell Stem Cell 4, 559–567

42. Kim, D. J., Chan, K. S., Sano, S., andDigiovanni, J. (2007) Signal transducer and activator of transcription 3 (Stat3) in epithelial carcinogenesis. Mol. Carcinog. 46, 725–731

43. Campbell, C. L., Jiang, Z., Savarese, D. M., and Savarese, T. M. (2001) Increased expression of the interleukin-11 receptor and evidence of STAT3 activation in prostate carcinoma. Am. J. Pathol. 158, 25–32

44. Zurita, A. J., Troncoso, P., Cardó-Vila, M., Logothetis, C. J., Pasqualini, R., andArap, W. (2004) Combinatorial screenings in patients. The interleukin-11 receptor as a candidate target in the progression of human prostate cancer. Cancer Res. 64, 435–439

45. Lewis, V. O., Ozawa, M. G., Deavers, M. T., Wang, G., Shintani, T., Arap, W., and Pasqualini, R. (2009) The interleukin-11 receptor α as a candidate ligand-directed target in osteosarcoma. Consistent data from cell lines, orthotopic models, and human tumor samples. Cancer Res. 69, 1995–1999

46. Nakayama, T., Yoshizaki, A., Izumida, S., Suehiro, T., Miura, S., Umura, T., Yakata, Y., Shichijio, K., Yamashita, S., and Seki, I. (2007) Expression of interleukin-11 (IL-11) and IL-11 receptor α in human gastric carcinoma and IL-11 up-regulates the invasive activity of human gastric carcinoma cells. Int. J. Oncol. 30, 825–833

47. Ernst, M., Najdovska, M., Grail, D., Lundgren-May, T., Buchert, M., Tye, H., Matthews, V. B., Armes, J., Bhathal, P. S., Hughes, N. R., Marcusson, E. G., Karras, J. G., Na, S., Sedgwick, J. D., Hertzog, P. J., and Jenkins, B. I. (2008) STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric carcinogenesis in gat130 receptor mutant mice. J. Clin. Invest. 118, 1727–1738

48. Chan, K. S., Sano, S., Kiguchi, K., Anders, J., Komazawa, N., Takeda, J., and DiGiovanni, J. (2004) Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J. Clin. Invest. 114, 720–728

49. Chan, K. S., Carabajal, S., Kiguchi, K., Clifford, J., Sano, S., and DiGiovanni, J. (2004) Epidermal growth factor receptor-mediated activation of Stat3 during multistage skin carcinogenesis. Cancer Res. 64, 2382–2389